Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

CD26 (Dipeptidyl peptidase 4) (DPP4) inhibitors + Synbiotics & Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Conclusions from randomized clinical trials (RCTs)

Bifidobacterium breve + Bifidobacterium longum + Fructooligosaccharides (FOS) + Lacticaseibacillus casei + Lacticaseibacillus rhamnosus + Lactobacillus acidophilus + Lactobacillus delbrueckii bulgaricus + Sitagliptin + Streptococcus thermophilus & Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD)

Bifidobacterium breve + Bifidobacterium longum + Fructooligosaccharides (FOS) + Lacticaseibacillus casei + Lacticaseibacillus rhamnosus + Lactobacillus acidophilus + Lactobacillus delbrueckii bulgaricus + Sitagliptin + Streptococcus thermophilus showed a greater improvement in fasting blood sugar (FBS), asp…

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

CD26 (Dipeptidyl peptidase 4) (DPP4) inhibitors + Synbiotics & Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD)

Welcome to meRfi Microbiome!

Navigation

Contents

Conclusions from randomized clinical trials (RCTs)

AI Chat